Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aytu BioScience to acquire Innovus Pharmaceuticals
This initial consideration to Innovus common shareholders is estimated to consist of approximately 4.2 million shares of Aytu stock. Additional consideration for up to $16 million in milestone
This initial consideration to Innovus common shareholders is estimated to consist of approximately 4.2 million shares of Aytu stock. Additional consideration for up to $16 million in milestone
Nucala is claimed to be the only targeted biologic to secure approval for the condition in the six to 11-year age group in the US. The FDA approval
Scientific teams from Atomwise and Hansoh Pharma will work closely together on the programs. The combination of complementary expertise and technologies has the potential to dramatically increase success
The trial is evaluating Tecentriq as a first-line (initial) monotherapy compared against cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung
Sitari has been developing a novel treatment for celiac disease and was the first company formed under the GSK-Avalon venture collaboration in 2013. Sitari was incubated at COI
The deal includes a fixed consideration of $175m (£141m), comprised of an upfront payment of $135 (£109m) and a long-term note for $40m (£32m), as well as contingent
“We’re pleased that the FDA has granted this designation for sotatercept,” said Janethe de Oliveira Pena, MD, PhD, Vice President, Pulmonary Medical Research at Acceleron. “In preclinical studies,
Imfinzi, along with four cycles of standard-of-care (SoC) chemotherapy, showed a statistically-significant and clinically-meaningful improvement in OS against SoC including up to six cycles of chemotherapy and optional
Topline data from the study were published on 3 July 20191, which showed a significant reduction in hyperglycemia, body weight and waist size compared to placebo. The entire
The phase III trial has demonstrated that Xofluza was a well-tolerated and efficient potential treatment for flu in otherwise healthy children aged one to less than 12 years